China approves first CAR T-cell therapy
BioSpectrum Asia|BioSpectrum Asia August 2021
Kite, a Gilead Company, has announced that Fosun Kite Biotechnology Co., Ltd.,

Continue reading your story on the app

Continue reading your story in the magazine

MORE STORIES FROM BIOSPECTRUM ASIAView All

How Personalised 3D-Printed Drugs Can Cut Costs & Eliminate Fakes

Although 3D printing in life sciences is mostly associated with organs, of late, 3D-printed drugs are also gaining traction. Let’s find out the benefits of this fast growing tech solution that promises to solve the industry’s manufacturing woes.

8 mins read
BioSpectrum Asia
BioSpectrum Asia April 2022

WHO Issues Guidelines To ‘Pandemic Influenza'

The World Health Organisation (WHO)’s new guidelines for the clinical management of severe illness from influenza virus infections provide recommendations on the use of influenza antivirals, adjunctive therapies and diagnostic strategies.

1 min read
BioSpectrum Asia
BioSpectrum Asia April 2022

Why Holomedicine Is Rapidly Gaining Ground

Medical holography has emerged as one of the most promising applications in the medical industry. Holographic imaging technology is advancing healthcare, life sciences, biomedical research as well as medical training and education. Mixed Reality (MR) applications are gradually making a progressive impact on healthcare deliveries with precise quantitative measurement of human internal anatomy elements in 3D holograms geometries displayed in actual physical space. Holographic 3D technology renders medical professionals with advanced diagnostic capabilities and surgical planning, by allowing them to slice virtual tissue, organs, and other body parts at various angles. Holomedicne advances access to percutaneous procedures without invasive needle techniques. Surgeons across the world are now curious to explore medical holograms to enhance the efficiency of complex surgeries.

10+ mins read
BioSpectrum Asia
BioSpectrum Asia April 2022

Pfizer's Oral Covid-19 Drug To Hit Shelves In 95 Countries

COVID-19 drug

1 min read
BioSpectrum Asia
BioSpectrum Asia April 2022

“We can only see interoperability driving the future of healthcare systems”

The need for having data sharing in healthcare through electronic records is more prevalent than ever. For the healthcare industry, big data can help lower rate of medication errors, facilitate preventive care, streamline staffing, among others. However due to the increasing number of cybersecurity attacks on healthcare systems, there is going to be more scrutiny regarding health data sharing, consent, and monetisation after recurring incidents exploiting interoperability.

4 mins read
BioSpectrum Asia
BioSpectrum Asia April 2022

“We are seeing strong demand for antiviral small molecules in APAC”

While vaccines have been rapidly developed and rolled out, there remains a dearth of small molecule treatment options that are designed specifically to combat COVID-19.

5 mins read
BioSpectrum Asia
BioSpectrum Asia April 2022

Waters introduces automated solution for mass and purity analysis of biomolecules

Waters Corporation has introduced new software and analytical columns to aid biomolecule drug discovery and development.

1 min read
BioSpectrum Asia
BioSpectrum Asia April 2022

RedHill inks $6M deal with Kukbo for COVID-19 drug in South Korea

RedHill Biopharma has entered into an exclusive licence agreement with Kukbo Co., a South Korean corporation, for oral opaganib for the treatment of COVID-19, in South Korea.

1 min read
BioSpectrum Asia
BioSpectrum Asia April 2022

Leveraging Academia-Industry Collabs to Scale-up S&T Innovations

Global challenges are too large to tackle in isolation. The creation of new shared value in public research through academic-industry collaborations are gaining momentum in innovations in the science, life science, biotechnology, and pharmaceutical industries.

4 mins read
BioSpectrum Asia
BioSpectrum Asia April 2022

Exploring the Possibilities of RNA Therapeutics

Fuelled by the successful utilisation of the mRNA COVID-19 vaccines, RNA therapeutics are expected to make larger strides in the near future. Let’s look at some of the drugs in late stage trials and the trends that will shape the RNA therapies landscape in 2022 and beyond:

6 mins read
BioSpectrum Asia
BioSpectrum Asia April 2022